Dr. Raymond Fong and the Raymond Fong Eye Care team in New York are dedicated to changing lives with quality eye care. EVO is a vision correction surgery that is a great option for many patients seeking to improve their vision. We are proud to offer the EVO ICL™ lens (EVO) at our NYC office.



Video in English

Vision Correction with EVO

EVO ICL is a clinically-proven implantable lens that corrects common vision problems such as nearsightedness (with or without astigmatism). Vision correction surgery with EVO allows patients to improve their vision to reduce or eliminate the need for glasses or contact lenses. ICL stands for implantable Collamer lens. Collamer is a proprietary material that is biocompatible, meaning it works in harmony with your natural eye.

picture of the EVO ICL lens

EVO ICL Vision Correction for Asian Eyes

At Raymond Fong Eye Care, we provide personalized care to each and every patient. We are especially highly regarded in the Asian community because we are skilled and experienced in meeting the specific needs of Asian patients. EVO ICL can be a good option for Asian patients because it is able to treat a high level of myopia (nearsightedness)—as high as -20D. People of Asian descent experience higher rates of high level myopia, compared to other ethnicities.1 Another advantage of EVO ICL for Asian patients is that it is an additive technology that does not remove corneal tissue. This is important because Asians tend to have thinner corneas than Caucasians.2

Benefits of EVO ICL

  • Provides crisp, clear vision2,3
  • Quick, safe, and minimally invasive procedure
  • Additive technology
  • Provides excellent night vision.5,6
  • Does not cause dry eye syndrome7,8
  • More than 3 million ICLS have been distributed worldwide
  • In a patient survey, 99.4% reported they would have the EVO procedure again.9
  • Collamer is a biocompatible material that also provides UV protection
  • Designed to be permanent, but can be removed by a doctor if needed

Who is a Candidate for EVO ICL?

EVO ICL is a great choice for many people seeking vision correction, including some patients who have been told they are not candidates for LASIK or other laser vision surgeries.
Good candidates for EVO ICL:

  • Are between the ages of 21 and 45
  • Have a stable prescription (no changes within the last year)
  • Seeking a solution for nearsightedness, with or without astigmatism

Jimmy O. Yang posing happily after EVO ICL surgery

An Overview of Vision Correction Surgery with EVO ICL

Preparing for EVO ICL

The first step is a consultation appointment. One of our experienced eye doctors will evaluate your vision and eye health in order to determine if EVO ICL is right for you. They will also answer any questions you have about the procedure. When you schedule your EVO ICL surgery, you will receive detailed pre-surgical instructions. You should plan to have a friend or family member transport you to and from your procedure.

Your EVO ICL Procedure

The actual EVO surgery typically takes less than 30 minutes. Your eyes will be numbed and anesthetic eye drops. Your eye surgeon will make a very small opening and insert the EVO lens. EVO ICL is implanted between your iris (the colored part of the eye) and your eye’s natural crystalline lens.

Recovery After EVO ICL

EVO requires minimal recovery time. You should plan to rest after your procedure and come back for a follow-up appointment the next day. Patients typically resume normal activities within two days.

Frequently Asked Questions about EVO ICL

What are the risks of EVO ICL?

EVO ICL is FDA approved and has an excellent safety record. Of course, any procedure carries some risk of side effects or complications. While rare, potential risks of EVO ICL include inflammation, need for additional procedures, and increased eye pressure.

Will the EVO lens be visible?

No, once the EVO lens is in place, only your eye doctor will be able to detect it.

Will I be able to feel the EVO lens?

No, patients should not be able to feel the EVO lens once it is in place.

How is EVO different from LASIK?

There are several key differences:

  • LASIK works by changing the shape of the cornea and removing tissue, while EVO works by adding an ICL to the eye.
  • EVO may be suitable for patients with dry eye concerns or thin corneas, two things that may disqualify people from having LASIK.
  • EVO can correct higher levels of nearsightedness.

Ultimately, you and your eye doctor can decide which procedure may be best for you.

Contact Us

We look forward to helping you improve your vision—and your life! Contact us to learn more about EVO or to schedule your free consultation appointment.



1 Yee-Ling Wong, Seang-Mei Saw, Epidemiology of Pathologic Myopia in Asia and Worldwide,
Asia-Pacific Journal of Ophthalmology, Volume 5, Issue 6, 2016, Pages 394-402, ISSN 2162-0989, https://doi.org/10.1097/APO.0000000000000234
2 Badr M, Masis Solano M, Amoozgar B, Nguyen A, Porco T, Lin S. Central Corneal Thickness Variances Among Different Asian Ethnicities in Glaucoma and Nonglaucoma Patients. J Glaucoma. 2019 Mar;28(3):223-230. doi: 10.1097/IJG.0000000000001180. PMID: 30624387.
3 Martínez-Plaza E, López-Miguel A, López-de la Rosa A, et al. Effect of the EVO+ Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life, Am J Ophthalmol 2021;226:117-125.
4 Packer M. Evaluation of the EVO/EVO+ Sphere and Toric Visian ICL: Six month results from the United States Food and Drug Administration clinical trial. Clinical Ophthalmology. 2022;16:1541-53.
5 Parkhurst GD. A prospective comparison of phakic collamer lenses and wavefront-optimized laser-assisted in situ keratomileusis for correction of myopia. Clin Ophthalmol. 2016;10:1209-1215.
6 Martínez-Plaza E, López-Miguel A, López-de la Rosa A, et al. Effect of the EVO+ Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life, Am J Ophthalmol 2021;226:117-125.
7 Ganesh S, Brar S, Pawar A. Matched population comparison of visual outcomes and patient satisfaction between 3 modalities for the correction of low to moderate myopic astigmatism. Clin Ophthalmol. 2017;11:1253-1263.
8 Naves J.S, Carracedo G, Cacho-Babillo I, Diadenosine nucleotid measurements as dry-eye score in patients after LASIK and ICL surgery. Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2012.
9 Packer M. The Implantable Collamer Lens with a central port: review of the literature. Clin Ophthalmol. 2018;12:2427-2438.